TWI522109B - 蕨素化合物用於治療糖尿病及肥胖之用途 - Google Patents

蕨素化合物用於治療糖尿病及肥胖之用途 Download PDF

Info

Publication number
TWI522109B
TWI522109B TW099102151A TW99102151A TWI522109B TW I522109 B TWI522109 B TW I522109B TW 099102151 A TW099102151 A TW 099102151A TW 99102151 A TW99102151 A TW 99102151A TW I522109 B TWI522109 B TW I522109B
Authority
TW
Taiwan
Prior art keywords
group
compound
fern
alkyl
alkynyl
Prior art date
Application number
TW099102151A
Other languages
English (en)
Chinese (zh)
Other versions
TW201039836A (en
Inventor
徐鳳麟
劉興華
汪炳鈞
Original Assignee
臺北醫學大學
國立台灣大學
國立清華大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 臺北醫學大學, 國立台灣大學, 國立清華大學 filed Critical 臺北醫學大學
Publication of TW201039836A publication Critical patent/TW201039836A/zh
Application granted granted Critical
Publication of TWI522109B publication Critical patent/TWI522109B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
TW099102151A 2009-01-26 2010-01-26 蕨素化合物用於治療糖尿病及肥胖之用途 TWI522109B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14738209P 2009-01-26 2009-01-26

Publications (2)

Publication Number Publication Date
TW201039836A TW201039836A (en) 2010-11-16
TWI522109B true TWI522109B (zh) 2016-02-21

Family

ID=42354647

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099102151A TWI522109B (zh) 2009-01-26 2010-01-26 蕨素化合物用於治療糖尿病及肥胖之用途

Country Status (10)

Country Link
US (1) US8633252B2 (enExample)
EP (1) EP2389171B1 (enExample)
JP (1) JP5640019B2 (enExample)
KR (1) KR101746867B1 (enExample)
CN (1) CN102333528B (enExample)
AU (1) AU2010206549B2 (enExample)
CA (1) CA2749931C (enExample)
NZ (1) NZ594236A (enExample)
TW (1) TWI522109B (enExample)
WO (1) WO2010085811A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014281768A1 (en) * 2013-06-19 2015-12-24 Access Business Group International Llc Plant-based inhibitors of ketohexokinase for the support of weight management
CN106831386A (zh) * 2015-12-04 2017-06-13 江西中医药大学 新型蕨素类化合物在治疗糖尿病的应用
CN105878220B (zh) * 2016-04-21 2019-02-05 广州市爱菩新医药科技有限公司 倍半萜类化合物在制备防治高血脂药物中的应用
CN107232497A (zh) * 2017-06-01 2017-10-10 河北农业大学 一种具有降血脂功能的膨化食品及其制备方法
WO2018230776A1 (ko) * 2017-06-16 2018-12-20 주식회사 코팜 프테로신 화합물 및 이의 유도체를 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
CN108576355B (zh) * 2018-03-27 2021-11-09 百色学院 一种蕨菜多糖含片及其制备方法
CN110156738B (zh) * 2019-06-26 2023-01-03 中北大学 一种伊鲁烷型倍半萜反应中间体及天然产物的全合成方法
CN117241792A (zh) * 2020-12-14 2023-12-15 Gh制药有限公司 包含蕨素化合物及其衍生物作为活性成分的用于预防或治疗pka相关疾病的药物组合物
KR20260019211A (ko) 2024-08-01 2026-02-10 주식회사 지에이치팜 프테로신 d의 신규한 합성 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745104A (en) * 1985-04-15 1988-05-17 The Regents Of The University Of California Pseudopterosin and synthetic derivatives thereof
US4849410A (en) * 1985-04-15 1989-07-18 The Regents Of The University Of California Pseudopterosin and synthetic derivatives thereof
JPS63146839A (ja) 1986-12-11 1988-06-18 Toa Nenryo Kogyo Kk プテロシン系化合物を含んで成る制癌剤
JPH02237932A (ja) * 1989-03-10 1990-09-20 Yokichi Mochizuki 結石等の治療剤
US5439936A (en) * 1989-10-03 1995-08-08 The Regents Of The University Of California Method of treating certain tumors using illudin analogs
HU224548B1 (hu) * 1993-04-07 2005-10-28 Taiho Pharmaceutical Co. Ltd. Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra
DE69719544T2 (de) 1996-12-12 2003-11-06 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
FR2777566B1 (fr) * 1998-04-15 2003-02-21 Synthelabo Derives d'azacycloalcanes, leur preparation et leur application en therapeutique
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
DE10142666A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142668A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6797287B2 (en) * 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
CA2703698C (en) * 2002-04-30 2016-11-22 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
AU2003287965A1 (en) * 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
AU2003277576A1 (en) * 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
FR2849849B1 (fr) * 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
EP1596877A4 (en) * 2003-02-26 2007-07-25 Unigen Pharmaceuticals Inc FORMULATION FOR USE IN THE PREVENTION AND TREATMENT OF DISEASES AND CONDITIONS CAUSED BY CARBOHYDRATES
CA2541212A1 (en) * 2003-11-04 2005-05-19 Wallace T. Ashton Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
EA011671B1 (ru) * 2004-06-04 2009-04-28 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
WO2006062933A2 (en) * 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Stable compositions of fenofibrate with fatty acid esters
FR2880885B1 (fr) * 2005-01-14 2009-01-30 Merck Sante Soc Par Actions Si Derives d'acide phenylbenzoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
KR20070107108A (ko) * 2005-02-05 2007-11-06 아스트라제네카 아베 화학적 화합물
US7582803B2 (en) * 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
US20080200458A1 (en) * 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders

Also Published As

Publication number Publication date
CN102333528B (zh) 2013-12-18
US20100190732A1 (en) 2010-07-29
JP5640019B2 (ja) 2014-12-10
KR20110125642A (ko) 2011-11-21
WO2010085811A9 (en) 2010-11-04
CA2749931A1 (en) 2010-07-29
JP2012515801A (ja) 2012-07-12
CN102333528A (zh) 2012-01-25
KR101746867B1 (ko) 2017-06-14
WO2010085811A2 (en) 2010-07-29
EP2389171A4 (en) 2012-10-10
AU2010206549A1 (en) 2011-08-11
US8633252B2 (en) 2014-01-21
CA2749931C (en) 2018-03-06
AU2010206549B2 (en) 2016-08-25
EP2389171A2 (en) 2011-11-30
TW201039836A (en) 2010-11-16
NZ594236A (en) 2014-08-29
AU2010206549A9 (en) 2016-08-25
EP2389171B1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
US8633252B2 (en) Use of pterosin compounds for treating diabetes and obesity
JP6517206B2 (ja) 新規肺線維症治療剤、その調整方法
BRPI0709962A2 (pt) licopeno para o tratamento de disfunção metabólica
WO2019104851A4 (zh) 一种β-羟基丁酰-氨基酸化合物及制备方法和应用
CN105753719A (zh) 一种盐酸曲恩汀化合物
KR20140102599A (ko) 뇌암 치료를 위한 방법 및 조성물
CN100418535C (zh) 一种七叶皂苷及其制备方法
CN101134042A (zh) 七叶皂苷的药物组合物及其制备方法和其用途
TWI833874B (zh) 神經變性疾病之預防或治療藥
CA3104916C (en) Pharmaceutical composition for preventing diabetes and use thereof
TW202404616A (zh) 鼠李糖在製備用於治療或預防神經退行性疾病的藥物中的用途、藥物組合物及其應用
KR100485936B1 (ko) 진세노사이드 Rh2 및 Rg3 항암 조성물
KR100759467B1 (ko) 차가버섯 또는 상황버섯으로부터 분리된 화합물을 함유하는통풍 예방 및 치료용 조성물
JP5109113B2 (ja) ＩｇＥ捕捉剤、並びに抗アレルギー性の医薬組成物、化粧料組成物、食料組成物、飲料組成物及び飼料組成物
JP2001335503A (ja) ラジカル消去用医薬品
KR20080094466A (ko) 대사증후군 치료용 약제 조성물
CN102743370B (zh) 双醋瑞因的用途
TW201742628A (zh) 錫蘭七指蕨、入地蜈蚣素及黃酮類化合物用於治療或預防新陳代謝疾病之用途
CN120053556A (zh) 百合莲子组合在改善肥胖与2型糖尿病中的应用
KR20240003190A (ko) 신주락톤 a를 포함하는 혈관 염증 치료용 조성물
JP2025134854A (ja) 筋疾患の予防又は治療用医薬組成物
KR20250178732A (ko) 홍삼박 유래 조 진토닌을 포함하는 치매 예방 또는 치료용 조성물
EP3474840A1 (en) Use of cyanoglucosides and pharmaceutical formulations thereof in the treatment of diabetes
CN121648111A (zh) 麦角硫因在制备改善代谢相关脂肪性肝病的药物中的应用
HK40055053A (en) Pharmaceutical composition comprising hydroquinone derivative for preventing or treating obesity or non-alcoholic steatohepatitis

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees